LexDanaLexDanabeta
Inventor

Venkata P. Palle

Inventor
Pune, IN

Overview

105→
Patents
2001–2021
Patent span
Human necessities
Primary field (CPC A)

Patents· 105 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations34%
C07DHeterocyclic compounds32%
A61KPreparations for medical, dental or toiletry purposes20%
C07HSugars9%
A61NElectrotherapy2%
C07CAcyclic or carbocyclic compounds2%
Y02ATechnologies for adaptation to climate change2%
C07BGeneral methods of organic chemistry0%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium0%
PatentTitleYear
11,040,974Crystalline linagliptin intermediate and process for preparation of linagliptin202110,292,981Oxazoline and isoxazoline derivatives as CRAC modulators2019RE0473512-(N-pyrazolo)adenosines with application as adenosine A201910,239,869Sulfonamide compounds as voltage-gated sodium channel modulators20199,987,249Substituted chroman compounds as calcium sensing receptor modulators20189,969,731Heterocyclyl compounds as MEK inhibitors20189,944,639Quinolizinone derivatives as PI3K inhibitors20189,827,247Heterocyclyl compounds20179,790,231'Chromane and chromene derivatives and their use as CRAC modulators'20179,737,534'Oxazoline and isoxazoline derivatives as CRAC modulators'20179,725,463'Substituted heterocyclic compounds as CRAC modulators'20179,617,211'Pyrrole derivatives as alpha 7 nAChR modulators'20179,617,210'Pyrrole derivatives as alpha 7 NACHR modulators'20179,598,371'Arylalkylamine compounds as calcium sensing receptor modulators'20179,598,391'Substituted chroman compounds as calcium sensing receptor modulators'20179,573,944'Heterocyclyl compounds'20179,555,035'Heterocyclyl compounds as MEK inhibitors'20179,504,680'Pyrrole derivatives as alpha 7 nAChR modulators'20169,493,396'Substituted naphthalene compounds as calcium sensing receptor modulators'20169,464,063'Benzo [B] [1,4] oxazin derivatives as calcium sensing receptor modulators'20169,447,037'4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1H-pyrrol-3-yl)benzenesulfonamide as alpha 7 nAChR modulator'20169,428,499'Heterocyclyl compounds as MEK inhibitors'20169,409,898'Substituted pyrazole compounds as CRAC modulators'20169,399,638'Substituted pyridine compounds as CRAC modulators'20169,393,247'Heteroaryl derivatives as alpha7 nAChR modulators'20169,388,196'Thiazole derivatives as alpha 7 nAChR modulators'20169,382,216'Substituted morpholines as modulators for the calcium sensing receptor'20169,359,367'Tetrahydroquinazolinone derivatives as PARP inhibitors'20169,284,316'Substituted fused pyrimidine compounds'20169,227,919'Arylalkylamine compounds as calcium sensing receptor modulators'20169,187,420'Pyrrole derivatives as nicotinic acetylcholine receptor modulators for use in the treatment of neurodegenerative disorders such as alzheimer\'s and parkinson\'s disease'20159,169,242'Oxazoline and isoxazoline derivatives as CRAC modulators'20159,163,001'Substituted chroman compounds as calcium sensing receptor modulators'20159,072,731'Heteroaryl derivatives as alpha7 nAChR modulators'20159,073,942'Antiviral compounds with a heterotricycle moiety'20159,073,943'Antiviral compounds with a dibenzooxaheterocycle moiety'20159,045,519'N-pyrazole A2A receptor agonists'20159,006,442'Cannabinoid receptor modulators'20159,000,175'Bicyclic GPR119 modulators'20158,946,432'Biaryl derivatives as nAChR modulators'20158,940,751'Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications'20158,940,900'2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application'20158,859,566'Substituted fused pyrimidine compounds'20148,846,910'Matrix metalloproteinase inhibitors'20148,816,073'Matrix metalloproteinase inhibitors'20148,796,290'Substituted fused pyrimidine compounds, its preparation and uses thereof'20148,710,261'5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other diseases'20148,569,260'N-pyrazole A2A receptor agonists'20138,507,670'Matrix metalloproteinase inhibitors'20138,501,955'Acetamide derivatives as glucokinase activators, their process and medicinal application'20138,420,666'Pyrazolo (3, 4-B) pyridine derivatives as phosphodiesterase inhibitors'20138,324,224'A2B adenosine receptor antagonists'20128,278,435'N-pyrazole A2A receptor agonists'20128,252,797'Heterocyclic compounds as adenosine receptor antagonist'20127,939,509'Partial and full agonists of A1 adenosine receptors'20117,915,286'Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors'20117,825,147'Inhibitors of phosphodiesterase type-IV'20107,795,269'A2B adenosine receptor antagonists'20107,781,460'Substituted indazoles as inhibitors of phosphodiesterase type-IV'20107,741,331'A2B adenosine receptor antagonists'20107,713,946'Partial and full agonists A1 adenosine receptors'20107,655,637'N-pyrazole A2A receptor agonists'20107,655,638'Partial and full agonists of A1 adenosine receptors'20107,566,717'Substituted heterocyclic compounds'20097,553,823'C-pyrazole A2A receptor agonists'20097,452,889'Substituted heterocyclic compounds'20087,317,017'A2B adenosine receptor antagonists'20087,304,070'A2B adenosine receptor antagonists'20077,262,176'Adenosine A3 receptor agonists'20077,262,198'Substituted heterocyclic compounds'20077,238,700'A2B adenosine receptor antagonists'20077,205,303'Substituted heterocyclic compounds'20077,183,264'N-pyrazole A2A receptor agonists'20077,163,928'Partial and full agonists of A1 adenosine receptors'20077,157,440'Partial and full agonists of A1 adenosine receptors'20077,144,872'N-pyrazole A2A receptor agonists'20067,115,610'Substituted heterocyclic compounds'20067,109,180'C-pyrazole A2A receptor agonists'20067,105,665'A2B adenosine receptor antagonists'20067,056,924'Substituted heterocyclic compounds'20067,026,321'Substituted heterocyclic compounds'20067,022,681'Partial and full agonists of A1 adenosine receptors'20067,001,909'Substituted heterocyclic compounds'20066,977,300'A2B adenosine receptor antagonists'20056,946,449'Partial and full agonists of A1 adenosine receptors'20056,930,111'Substituted heterocyclic compounds'20056,855,818'C-pyrazole A2A receptor agonists'20056,852,723'Aralkyl substituted piperazine compounds'20056,849,632'Heteroaryl alkyl piperazine derivatives'20056,825,349'A2B adenosine receptor antagonists'20046,770,651'A2B adenosine receptor antagonists'20046,770,634'C-pyrazole a2a receptor agonists'20046,677,336'Substituted piperazine compounds'20046,642,210'2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists'20036,605,597'Partial or full A1agonists-N-6 heterocyclic 5-thio substituted adenosine derivatives'20036,576,619'Orally active A1 adenosine receptor agonists'20036,573,264'Heteroaryl alkyl piperazine derivatives'20036,552,023'Aralkyl substituted piperazine compounds'20036,451,798'Substituted alkyl piperazine derivatives'20026,440,948'Thiophene A2A receptor agonists'20026,403,567'N-pyrazole A2A adenosine receptor agonists'20026,294,522'N6 heterocyclic 8-modified adenosine derivatives'20016,258,793'N6 heterocyclic 5\' modified adenosine derivatives'20016,214,807'C-pyrazole 2A A receptor agonists'20016,180,615'Propargyl phenyl ether A2A receptor agonists'2001

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2001–2010Patents assigned to CV THERAPEUTICS INC (40)· patent assignee history
2001–2005Based in Mountain View, CA, US· patent location history
2003–2019Based in Sunnyvale, CA, US· patent location history
2004–2009Based in Gurgaon, IN· patent location history
2007–2018Based in Pune, IN· patent location history
2010–2014Patents assigned to RANBAXY LAB LTD (8)· patent assignee history
2013–2016Patents assigned to PALLE VENKATA P (13)· patent assignee history
2013–2019Based in Maharashtra, IN· patent location history
2015–2019Patents assigned to LUPIN LTD (33)· patent assignee history
2015–2016Patents assigned to KAMBOJ RAJENDER KUMAR (8)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
CV THERAPEUTICS INC402001–2010
LUPIN LTD332015–2019
PALLE VENKATA Pself132013–2016
KAMBOJ RAJENDER KUMAR82015–2016
RANBAXY LAB LTD82010–2014
Locations
LocationPatentsSpan
Pune, IN432007–2018
Gurgaon, IN192004–2009
Maharashtra, IN142013–2019
Mountain View, California, US132001–2005
Sunnyvale, California, US72003–2019